Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GERARD JOSEPH MESKILL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1295975324
CMS profile
240606
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$241,753.62

293 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $92,512.76 102
JAZZ PHARMACEUTICALS INC. $64,315.00 70
Axsome Therapeutics, Inc. $44,251.34 46
Avadel CNS Pharmaceuticals, LLC $30,216.03 55
HARMONY BIOSCIENCES LLC $10,400.93 17
IDORSIA PHARMACEUTICALS US INC $37.46 2
Azurity Pharmaceuticals, Inc. $20.10 1

Page 5 of 6; records 201–250 of 293 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GERARD JOSEPH MESKILL

NPI 1295975324 · CMS profile ID 240606

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 293 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295975324?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GERARD JOSEPH MESKILL, NPI 1295975324, CMS profile ID 240606. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 293 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295975324?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GERARD JOSEPH MESKILL, NPI 1295975324, CMS profile ID 240606. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 293 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295975324?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GERARD JOSEPH MESKILL, NPI 1295975324, CMS profile ID 240606, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 293 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295975324?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

293 matching records · $241,753.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 293 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 293.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $1,050.0004/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186642771 CMS
Lilly USA, LLC $1,050.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186575118 CMS
JAZZ PHARMACEUTICALS INC. $2,940.0004/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299594 CMS
JAZZ PHARMACEUTICALS INC. $176.5104/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234303025 CMS
JAZZ PHARMACEUTICALS INC. $121.7804/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234307112 CMS
Axsome Therapeutics, Inc. $5,625.5004/18/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235753057 CMS
Axsome Therapeutics, Inc. $76.4404/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235805153 CMS
Axsome Therapeutics, Inc. $8.7704/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235805159 CMS
Avadel CNS Pharmaceuticals, LLC $3,800.0004/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538316 CMS
Avadel CNS Pharmaceuticals, LLC $487.9504/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208538318 CMS
Avadel CNS Pharmaceuticals, LLC $3,800.0004/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538310 CMS
Avadel CNS Pharmaceuticals, LLC $660.9604/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208538312 CMS
Avadel CNS Pharmaceuticals, LLC $138.5704/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538314 CMS
Avadel CNS Pharmaceuticals, LLC $200.0004/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538308 CMS
Lilly USA, LLC $1,850.0004/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186618858 CMS
Lilly USA, LLC $2,100.0004/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186642767 CMS
Avadel CNS Pharmaceuticals, LLC $15.1504/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538306 CMS
JAZZ PHARMACEUTICALS INC. $2,695.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299668 CMS
JAZZ PHARMACEUTICALS INC. $100.0404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234308766 CMS
Lilly USA, LLC $177.5304/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186575114 CMS
Lilly USA, LLC $140.3104/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186575116 CMS
Lilly USA, LLC $17.6504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186618860 CMS
Avadel CNS Pharmaceuticals, LLC $6.7404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538304 CMS
Lilly USA, LLC $14.3804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186560980 CMS
Lilly USA, LLC $2,100.0004/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186596446 CMS
Lilly USA, LLC $1,325.0004/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186630889 CMS
Lilly USA, LLC $2,100.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186596448 CMS
Lilly USA, LLC $1,050.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186596450 CMS
Lilly USA, LLC $1,325.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186642763 CMS
Lilly USA, LLC $1,050.0004/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186642765 CMS
Lilly USA, LLC $121.8604/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186618856 CMS
Lilly USA, LLC $2,100.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186575110 CMS
Lilly USA, LLC $1,850.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186618848 CMS
Lilly USA, LLC $135.7404/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186606796 CMS
Lilly USA, LLC $143.4904/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186630887 CMS
Lilly USA, LLC $13.5104/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186630891 CMS
Lilly USA, LLC $1,050.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186647917 CMS
Avadel CNS Pharmaceuticals, LLC $1,600.0003/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538302 CMS
Lilly USA, LLC $1,050.0003/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186642761 CMS
Avadel CNS Pharmaceuticals, LLC $8.5103/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538300 CMS
Lilly USA, LLC $1,050.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186596444 CMS
Avadel CNS Pharmaceuticals, LLC $116.3903/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538298 CMS
Lilly USA, LLC $1,050.0003/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186630885 CMS
Lilly USA, LLC $2,100.0003/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186647913 CMS
Lilly USA, LLC $1,325.0003/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186647915 CMS
Lilly USA, LLC $61.0303/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186618854 CMS
Lilly USA, LLC $1,325.0003/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186560978 CMS
Lilly USA, LLC $2,100.0003/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186618850 CMS
Avadel CNS Pharmaceuticals, LLC $31.2603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538296 CMS
JAZZ PHARMACEUTICALS INC. $27.3003/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234325955 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $93,102.16 161
PY2020 $72,138.02 90
PY2021 $108,418.66 127
PY2022 $112,761.97 159
PY2023 $235,368.09 289
PY2024 $183,667.68 240
PY2025 $241,753.62 293

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $763,317.94 429
PY2024 Principal investigator $30,898.58 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

429 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $2,478.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614621
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618553
Principal investigator 1 Alkermes, Inc. $1,849.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619469
Principal investigator 1 Alkermes, Inc. $839.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619723
Principal investigator 1 Alkermes, Inc. $2,478.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622119
Principal investigator 1 Alkermes, Inc. $2,478.00 12/23/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625209
Principal investigator 1 Alkermes, Inc. $289.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614615
Principal investigator 1 Alkermes, Inc. $2,340.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618541
Principal investigator 1 Alkermes, Inc. $2,673.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618979
Principal investigator 1 Alkermes, Inc. $347.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619959
Principal investigator 1 Alkermes, Inc. $2,167.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622545
Principal investigator 1 Alkermes, Inc. $839.00 12/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626506
Principal investigator 1 Alkermes, Inc. $68.40 12/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622745
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745226
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745228
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.84 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745230
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745232
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745234
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.28 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745236
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745238
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745240
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.03 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745242
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745244
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745246
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.12 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745248
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.98 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745250
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745252
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.76 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745254
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745256
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32.70 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745258
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745260
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $91.22 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745262
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 11/24/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745264
Principal investigator 1 Alkermes, Inc. $839.00 11/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614184
Principal investigator 1 Alkermes, Inc. $5,332.00 11/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616979
Principal investigator 1 Alkermes, Inc. $6,945.00 11/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621672
Principal investigator 1 Alkermes, Inc. $5,591.00 11/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624364
Principal investigator 1 Alkermes, Inc. $2,213.00 11/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625916
Principal investigator 1 Alkermes, Inc. $744.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613109
Principal investigator 1 Alkermes, Inc. $744.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614180
Principal investigator 1 Alkermes, Inc. $2,167.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614617
Principal investigator 1 Alkermes, Inc. $5,271.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614855
Principal investigator 1 Alkermes, Inc. $289.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616553
Principal investigator 1 Alkermes, Inc. $2,179.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617185
Principal investigator 1 Alkermes, Inc. $744.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617787
Principal investigator 1 Alkermes, Inc. $2,673.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618543
Principal investigator 1 Alkermes, Inc. $837.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618765
Principal investigator 1 Alkermes, Inc. $289.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619463
Principal investigator 1 Alkermes, Inc. $289.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620185
Principal investigator 1 Alkermes, Inc. $289.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620840
Principal investigator 1 Alkermes, Inc. $7,167.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621462
Principal investigator 1 Alkermes, Inc. $744.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626716
Principal investigator 1 Alkermes, Inc. $837.00 11/12/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626969
Principal investigator 1 Alkermes, Inc. $2,293.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613527
Principal investigator 1 Alkermes, Inc. $2,293.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614861
Principal investigator 1 Alkermes, Inc. $1,279.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615259
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615431
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615657
Principal investigator 1 Alkermes, Inc. $2,293.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616343
Principal investigator 1 Alkermes, Inc. $1,279.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616981
Principal investigator 1 Alkermes, Inc. $2,293.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618991
Principal investigator 1 Alkermes, Inc. $347.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619963
Principal investigator 1 Alkermes, Inc. $1,279.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621468
Principal investigator 1 Alkermes, Inc. $2,293.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621470
Principal investigator 1 Alkermes, Inc. $347.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623488
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623692
Principal investigator 1 Alkermes, Inc. $347.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623896
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623898
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624370
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624372
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625463
Principal investigator 1 Alkermes, Inc. $289.00 11/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626983
Principal investigator 1 Alkermes, Inc. $54.72 11/07/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614182
Principal investigator 1 Alkermes, Inc. $54.72 11/07/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620405
Principal investigator 1 Alkermes, Inc. $13.68 11/07/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623892
Principal investigator 1 Alkermes, Inc. $141.35 11/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614404
Principal investigator 1 Alkermes, Inc. $16.00 11/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622115
Principal investigator 1 Alkermes, Inc. $3.85 11/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622325
Principal investigator 1 Alkermes, Inc. $7,500.00 10/27/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624995
Principal investigator 1 Alkermes, Inc. $289.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613523
Principal investigator 1 Alkermes, Inc. $6,449.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614406
Principal investigator 1 Alkermes, Inc. $6,945.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616097
Principal investigator 1 Alkermes, Inc. $744.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617189
Principal investigator 1 Alkermes, Inc. $3,790.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618035
Principal investigator 1 Alkermes, Inc. $2,387.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620409
Principal investigator 1 Alkermes, Inc. $2,315.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620411
Principal investigator 1 Alkermes, Inc. $5,591.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622327
Principal investigator 1 Alkermes, Inc. $6,945.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623240
Principal investigator 1 Alkermes, Inc. $2,213.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623894
Principal investigator 1 Alkermes, Inc. $5,591.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624116
Principal investigator 1 Alkermes, Inc. $4,409.00 10/22/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625459
Principal investigator 1 Alkermes, Inc. $2,673.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613117
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615429
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615433
Principal investigator 1 Alkermes, Inc. $744.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616091
Principal investigator 1 Alkermes, Inc. $5,103.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616339
Principal investigator 1 Alkermes, Inc. $2,673.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616551
Principal investigator 1 Alkermes, Inc. $2,673.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616737
Principal investigator 1 Alkermes, Inc. $2,167.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617191
Principal investigator 1 Alkermes, Inc. $837.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618761
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618769
Principal investigator 1 Alkermes, Inc. $2,179.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619461
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620399
Principal investigator 1 Alkermes, Inc. $7,167.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620634
Principal investigator 1 Alkermes, Inc. $2,673.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621260
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621460
Principal investigator 1 Alkermes, Inc. $2,167.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621472
Principal investigator 1 Alkermes, Inc. $837.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621676
Principal investigator 1 Alkermes, Inc. $2,673.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621678
Principal investigator 1 Alkermes, Inc. $2,179.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621907
Principal investigator 1 Alkermes, Inc. $5,271.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622317
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622319
Principal investigator 1 Alkermes, Inc. $837.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622996
Principal investigator 1 Alkermes, Inc. $2,179.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625457
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625690
Principal investigator 1 Alkermes, Inc. $837.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626512
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626514
Principal investigator 1 Alkermes, Inc. $289.00 10/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626720
Principal investigator 1 Alkermes, Inc. $289.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613974
Principal investigator 1 Alkermes, Inc. $289.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615085
Principal investigator 1 Alkermes, Inc. $289.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615901
Principal investigator 1 Alkermes, Inc. $2,293.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620842
Principal investigator 1 Alkermes, Inc. $1,279.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621466
Principal investigator 1 Alkermes, Inc. $289.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624798
Principal investigator 1 Alkermes, Inc. $289.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624800
Principal investigator 1 Alkermes, Inc. $1,279.00 10/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625461
Principal investigator 1 Alkermes, Inc. $2.61 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613111
Principal investigator 1 Alkermes, Inc. $38.55 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613521
Principal investigator 1 Alkermes, Inc. $1.40 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614402
Principal investigator 1 Alkermes, Inc. $25.00 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614619
Principal investigator 1 Alkermes, Inc. $12.85 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616093
Principal investigator 1 Alkermes, Inc. $18.20 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616095
Principal investigator 1 Alkermes, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616555
Principal investigator 1 Alkermes, Inc. $111.36 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617589
Principal investigator 1 Alkermes, Inc. $17.10 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617789
Principal investigator 1 Alkermes, Inc. $51.40 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618033
Principal investigator 1 Alkermes, Inc. $1.05 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618545
Principal investigator 1 Alkermes, Inc. $2.14 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618981
Principal investigator 1 Alkermes, Inc. $16.00 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618983
Principal investigator 1 Alkermes, Inc. $0.35 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620636
Principal investigator 1 Alkermes, Inc. $0.70 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621670
Principal investigator 1 Alkermes, Inc. $12.85 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622321
Principal investigator 1 Alkermes, Inc. $25.68 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623888
Principal investigator 1 Alkermes, Inc. $65.45 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623890
Principal investigator 1 Alkermes, Inc. $12.85 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625207
Principal investigator 1 Alkermes, Inc. $2.10 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626310
Principal investigator 1 Alkermes, Inc. $77.10 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626971
Principal investigator 1 Alkermes, Inc. $0.35 10/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626977
Principal investigator 1 Alkermes, Inc. $744.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619291
Principal investigator 1 Alkermes, Inc. $5,332.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620486
Principal investigator 1 Alkermes, Inc. $289.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621528
Principal investigator 1 Alkermes, Inc. $744.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622421
Principal investigator 1 Alkermes, Inc. $2,315.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625788
Principal investigator 1 Alkermes, Inc. $5,332.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625974
Principal investigator 1 Alkermes, Inc. $2,315.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626360
Principal investigator 1 Alkermes, Inc. $2,213.00 09/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626806
Principal investigator 1 Alkermes, Inc. $2,546.57 09/17/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613055
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208612961
Principal investigator 1 Alkermes, Inc. $2,387.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613273
Principal investigator 1 Alkermes, Inc. $7,167.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613786
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614260
Principal investigator 1 Alkermes, Inc. $7,167.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614471
Principal investigator 1 Alkermes, Inc. $1,279.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614721
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614933
Principal investigator 1 Alkermes, Inc. $7,167.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615487
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615611
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615973
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616177
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616529
Principal investigator 1 Alkermes, Inc. $7,167.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616601
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616801
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616803
Principal investigator 1 Alkermes, Inc. $5,103.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616923
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617441
Principal investigator 1 Alkermes, Inc. $7,167.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617449
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617641
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617643
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619059
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619197
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619293
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619301
Principal investigator 1 Alkermes, Inc. $6,672.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619557
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620147
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620490
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621224
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621316
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621318
Principal investigator 1 Alkermes, Inc. $5,271.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622197
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622417
Principal investigator 1 Alkermes, Inc. $2,673.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622603
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623960
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623966
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624186
Principal investigator 1 Alkermes, Inc. $4,233.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624430
Principal investigator 1 Alkermes, Inc. $2,179.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624877
Principal investigator 1 Alkermes, Inc. $289.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625085
Principal investigator 1 Alkermes, Inc. $2,282.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625417
Principal investigator 1 Alkermes, Inc. $3,790.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625784
Principal investigator 1 Alkermes, Inc. $837.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625964
Principal investigator 1 Alkermes, Inc. $5,271.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625966
Principal investigator 1 Alkermes, Inc. $5,271.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625970
Principal investigator 1 Alkermes, Inc. $744.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625978
Principal investigator 1 Alkermes, Inc. $5,271.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626178
Principal investigator 1 Alkermes, Inc. $5,271.00 09/08/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626180
Principal investigator 1 Alkermes, Inc. $1.75 09/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614929
Principal investigator 1 Alkermes, Inc. $1.40 09/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614931
Principal investigator 1 Alkermes, Inc. $42.80 09/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619551
Principal investigator 1 Alkermes, Inc. $2.14 09/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623060
Principal investigator 1 Alkermes, Inc. $93.50 09/04/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626580
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614258
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615735
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616169
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617253
Principal investigator 1 Alkermes, Inc. $7,500.00 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618359
Principal investigator 1 Alkermes, Inc. $92.75 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620251
Principal investigator 1 Alkermes, Inc. $1,879.00 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620778
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621516
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622411
Principal investigator 1 Alkermes, Inc. $1,879.00 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624636
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626166
Principal investigator 1 Alkermes, Inc. $7,500.00 09/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626256
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,494.32 08/21/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745216
Principal investigator 1 Alkermes, Inc. $6,449.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613571
Principal investigator 1 Alkermes, Inc. $4,409.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614473
Principal investigator 1 Alkermes, Inc. $2,387.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614711
Principal investigator 1 Alkermes, Inc. $744.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614935
Principal investigator 1 Alkermes, Inc. $3,790.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616415
Principal investigator 1 Alkermes, Inc. $3,790.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617645
Principal investigator 1 Alkermes, Inc. $289.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620047
Principal investigator 1 Alkermes, Inc. $2,387.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621126
Principal investigator 1 Alkermes, Inc. $289.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621730
Principal investigator 1 Alkermes, Inc. $4,409.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623546
Principal investigator 1 Alkermes, Inc. $6,449.00 08/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625307
Principal investigator 1 Alkermes, Inc. $270.26 08/15/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614465
Principal investigator 1 Alkermes, Inc. $70.00 08/14/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614208
Principal investigator 1 Alkermes, Inc. $5,103.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613035
Principal investigator 1 Alkermes, Inc. $744.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613886
Principal investigator 1 Alkermes, Inc. $744.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614551
Principal investigator 1 Alkermes, Inc. $744.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615201
Principal investigator 1 Alkermes, Inc. $2,282.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615385
Principal investigator 1 Alkermes, Inc. $5,103.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615823
Principal investigator 1 Alkermes, Inc. $2,387.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615825
Principal investigator 1 Alkermes, Inc. $5,103.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616035
Principal investigator 1 Alkermes, Inc. $2,282.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617119
Principal investigator 1 Alkermes, Inc. $2,179.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617371
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617719
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617959
Principal investigator 1 Alkermes, Inc. $744.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619669
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619889
Principal investigator 1 Alkermes, Inc. $3,790.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619921
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620329
Principal investigator 1 Alkermes, Inc. $5,103.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621198
Principal investigator 1 Alkermes, Inc. $2,282.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621392
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621420
Principal investigator 1 Alkermes, Inc. $289.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621835
Principal investigator 1 Alkermes, Inc. $7,167.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622041
Principal investigator 1 Alkermes, Inc. $5,103.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622045
Principal investigator 1 Alkermes, Inc. $2,282.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622049
Principal investigator 1 Alkermes, Inc. $744.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622075
Principal investigator 1 Alkermes, Inc. $5,271.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623626
Principal investigator 1 Alkermes, Inc. $2,282.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623814
Principal investigator 1 Alkermes, Inc. $2,179.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624919
Principal investigator 1 Alkermes, Inc. $6,672.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626466
Principal investigator 1 Alkermes, Inc. $2,478.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626686
Principal investigator 1 Alkermes, Inc. $4,233.00 08/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626688
Principal investigator 1 Alkermes, Inc. $41.04 08/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626578
Principal investigator 1 Alkermes, Inc. $51.40 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614705
Principal investigator 1 Alkermes, Inc. $218.40 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616605
Principal investigator 1 Alkermes, Inc. $12.85 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617035
Principal investigator 1 Alkermes, Inc. $36.40 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617451
Principal investigator 1 Alkermes, Inc. $46.75 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617853
Principal investigator 1 Alkermes, Inc. $4.35 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620482
Principal investigator 1 Alkermes, Inc. $1.05 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620902
Principal investigator 1 Alkermes, Inc. $4.55 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622409
Principal investigator 1 Alkermes, Inc. $64.25 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622595
Principal investigator 1 Alkermes, Inc. $12.85 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622609
Principal investigator 1 Alkermes, Inc. $12.85 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622803
Principal investigator 1 Alkermes, Inc. $25.68 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623314
Principal investigator 1 Alkermes, Inc. $12.80 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623552
Principal investigator 1 Alkermes, Inc. $185.60 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625776
Principal investigator 1 Alkermes, Inc. $46.75 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625960
Principal investigator 1 Alkermes, Inc. $4.28 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626160
Principal investigator 1 Alkermes, Inc. $12.80 08/05/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626366
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/28/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745218
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 07/28/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745220
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $993.00 07/28/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745222
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 07/28/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745224
Principal investigator 1 Alkermes, Inc. $2,560.00 07/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613393
Principal investigator 1 Alkermes, Inc. $1,200.00 07/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617257
Principal investigator 1 Alkermes, Inc. $3,840.00 07/25/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617861
Principal investigator 1 Alkermes, Inc. $1,196.53 07/21/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615687
Principal investigator 1 Alkermes, Inc. $1,196.53 07/21/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620439
Principal investigator 1 Alkermes, Inc. $1,196.53 07/21/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625027
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613051
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613892
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614124
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614126
Principal investigator 1 Alkermes, Inc. $2,478.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614563
Principal investigator 1 Alkermes, Inc. $1,673.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615205
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615207
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616039
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616265
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616269
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616901
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617341
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617731
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618455
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618459
Principal investigator 1 Alkermes, Inc. $2,282.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619175
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619413
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619651
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620121
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620343
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620576
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620582
Principal investigator 1 Alkermes, Inc. $1,673.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620772
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621202
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621606
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621608
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622055
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622257
Principal investigator 1 Alkermes, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622265
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622267
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622681
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622924
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623628
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624058
Principal investigator 1 Alkermes, Inc. $5,103.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624060
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624302
Principal investigator 1 Alkermes, Inc. $6,672.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624714
Principal investigator 1 Alkermes, Inc. $2,179.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624716
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624921
Principal investigator 1 Alkermes, Inc. $289.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624923
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625636
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626434
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626438
Principal investigator 1 Alkermes, Inc. $4,233.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626660
Principal investigator 1 Alkermes, Inc. $3,790.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626890
Principal investigator 1 Alkermes, Inc. $744.00 07/16/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626892
Principal investigator 1 Alkermes, Inc. $2,400.00 07/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613259
Principal investigator 1 Alkermes, Inc. $5,120.00 07/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618453
Principal investigator 1 Alkermes, Inc. $7,680.00 07/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620770
Principal investigator 1 Alkermes, Inc. $10.70 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613173
Principal investigator 1 Alkermes, Inc. $0.70 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613581
Principal investigator 1 Alkermes, Inc. $8.04 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614923
Principal investigator 1 Alkermes, Inc. $36.40 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616409
Principal investigator 1 Alkermes, Inc. $36.40 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617039
Principal investigator 1 Alkermes, Inc. $0.70 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617849
Principal investigator 1 Alkermes, Inc. $8.04 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617869
Principal investigator 1 Alkermes, Inc. $51.40 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618127
Principal investigator 1 Alkermes, Inc. $0.16 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621963
Principal investigator 1 Alkermes, Inc. $65.45 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623058
Principal investigator 1 Alkermes, Inc. $1.75 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625768
Principal investigator 1 Alkermes, Inc. $91.00 07/02/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626156
Principal investigator 1 Alkermes, Inc. $7,500.00 06/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613295
Principal investigator 1 Alkermes, Inc. $1,879.00 06/20/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625185
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616815
Principal investigator 1 Alkermes, Inc. $128.50 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617049
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617069
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617075
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618319
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620279
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620660
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620710
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620726
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620928
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620944
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622453
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622821
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623082
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623496
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623918
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624154
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624244
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624895
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625105
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625115
Principal investigator 1 Alkermes, Inc. $8.04 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625519
Principal investigator 1 Alkermes, Inc. $36.40 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625565
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625569
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626520
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626862
Principal investigator 1 Alkermes, Inc. $2,478.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613081
Principal investigator 1 Alkermes, Inc. $6,672.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613928
Principal investigator 1 Alkermes, Inc. $2,282.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614152
Principal investigator 1 Alkermes, Inc. $3,790.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618505
Principal investigator 1 Alkermes, Inc. $744.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620810
Principal investigator 1 Alkermes, Inc. $289.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622715
Principal investigator 1 Alkermes, Inc. $744.00 06/11/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626478
Principal investigator 1 Alkermes, Inc. $113.34 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617273
Principal investigator 1 Alkermes, Inc. $259.54 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617653
Principal investigator 1 Alkermes, Inc. $52.48 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619079
Principal investigator 1 Alkermes, Inc. $95.76 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620714
Principal investigator 1 Alkermes, Inc. $119.36 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621975
Principal investigator 1 Alkermes, Inc. $56.85 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621979
Principal investigator 1 Alkermes, Inc. $77.64 06/06/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622617
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $81.90 05/09/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745212
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,400.00 05/09/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745214
Principal investigator 1 Alkermes, Inc. $1,196.53 05/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616991
Principal investigator 1 Alkermes, Inc. $1,045.00 04/21/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616745
Principal investigator 1 Alkermes, Inc. $3,756.00 03/18/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623690
Principal investigator 1 Alkermes, Inc. $610.00 03/10/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617187
Principal investigator 1 Alkermes, Inc. $47.75 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617169
Principal investigator 1 Alkermes, Inc. $16.00 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617771
Principal investigator 1 Alkermes, Inc. $100.30 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619947
Principal investigator 1 Alkermes, Inc. $218.45 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620828
Principal investigator 1 Alkermes, Inc. $50.00 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622737
Principal investigator 1 Alkermes, Inc. $412.40 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623872
Principal investigator 1 Alkermes, Inc. $22.50 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624546
Principal investigator 1 Alkermes, Inc. $70.40 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624985
Principal investigator 1 Alkermes, Inc. $162.05 03/03/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625201
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 03/03/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745208
Principal investigator 1 Alkermes, Inc. $1,770.00 02/28/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620740
Principal investigator 1 Alkermes, Inc. $1,770.00 02/28/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624264
Principal investigator 1 Alkermes, Inc. $70.00 02/27/2025 Non-covered Recipient Entity
CLINICAL NEUROPHYSIOLOGY SERVICES PC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624042
Principal investigator 1 Alkermes, Inc. $650.00 02/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618183
Principal investigator 1 Alkermes, Inc. $290.00 02/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618687
Principal investigator 1 Alkermes, Inc. $650.00 02/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620303
Principal investigator 1 Alkermes, Inc. $290.00 02/19/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620970
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $547.56 02/03/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745200
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $800.80 02/03/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745202
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,590.14 02/03/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745210
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,528.60 01/17/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745196
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 01/17/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745198
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,455.20 01/17/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745204
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 01/17/2025 Non-covered Recipient Entity
Tricoastal Narcolepsy and Sleep Disorders Center, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745206
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627090
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627168
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
TRICOASTAL NARCOLEPSY AND SLEEP DISORDERS CENTER, PLLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627238